Use of physiological doses of human growth hormone in haematological patients receiving intensive chemotherapy promotes haematopoietic recovery: a double-blind randomized, placebo-controlled study

Sirohi, Bhawna; Powles, R; Morgan, Gareth J.; Treleaven, J; Kulkarni, Samar; Horton, C; Sašo, Radovan; Rolfe, Debbie; Cook, Gary; Shaw, Catriona; Wass, John

doi:10.1038/sj.bmt.1705545

Cited by 15 publications

(6 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…GH and IGF-1 are FDA-approved agents for the treatment of GH non-responsiveness in the general population of children with GH hyporesponsiveness or primary IGF-1 deficiencies. Recently, a double-blind clinical study in patients receiving intensive chemotherapy for various leukemias and lymphomas revealed that administration of GH caused significantly faster platelet recovery [60]. Notch-based culture systems have been used to generate T cells from human cord blood and human adult BM derived CD34 + progenitor cells, indicating that this technique can be converted to a clinically applicable therapeutic method [61;62;63].…”

Section: Clinical Perspectivesmentioning

confidence: 99%

Enhancing T cell reconstitution after hematopoietic stem cell transplantation: A brief update of the latest trends

Zakrzewski

Goldberg

Smith

et al. 2008

Blood Cells, Molecules, and Diseases

View full text Add to dashboard Cite

Hematopoietic stem cell transplantation (HSCT) is associated with a period of immune incompetence that particularly affects the T cell lineage. Strategies to enhance T cell reconstitution could significantly improve the survival of HSCT recipients by decreasing the incidence of fatal infectious complications and by enhancing graft-versus-tumor activity. In recent years, a variety of promising strategies have been established in preclinical models to improve T cell recovery in particular after allogeneic T cell-depleted HSCT, without aggravating graft-versus-host disease while preserving or even improving graft-versus-tumor activity. These therapies include treatment with keratinocyte growth factor (KGF), growth hormone (GH), LHRH agonists, interleukin 7 (IL-7) and interleukin 15 (IL-15). Thanks to the establishment of Notch-based culture systems, adoptive cellular therapies with T lineage-committed precursor cells have become feasible, since early T cell progenitors can now easily be generated in vitro in large quantities and have been proven to be very effective in enhancing T cell reconstitution and anti-tumor activity after allogeneic T cell-depleted HSCT. The translation of most of these strategies into clinical trials is likely and in some cases Phase I/II studies are already underway.

show abstract

Section: Clinical Perspectivesmentioning

confidence: 99%

Enhancing T cell reconstitution after hematopoietic stem cell transplantation: A brief update of the latest trends

Zakrzewski

Goldberg

Smith

et al. 2008

Blood Cells, Molecules, and Diseases

View full text Add to dashboard Cite

show abstract

“…In clinical settings, GH therapy after chemotherapy raises many concerns due to the possible growth-promoting effects on tumor cells. In a more recent study [10], patients with hematological malignancies who had received intensive chemotherapy were given rhGH (500 micrograms/day) or placebo for 6 weeks. There was no difference in the time to relapse between groups and the GH-treated patients had accelerated platelet recovery.…”

Section: Bone Marrow Transplantationmentioning

confidence: 99%

Neuroendocrine hormones such as growth hormone and prolactin are integral members of the immunological cytokine network

Redelman¹,

Taub

et al. 2008

Cellular Immunology

View full text Add to dashboard Cite

Neuroendocrine hormones such as growth hormone (GH) and prolactin (PRL) have been demonstrated to accelerate the recovery of the immune response after chemotherapy and bone marrow transplantation and to enhance the restoration of immunity in individuals infected with HIV and in normal individuals with compromised immune systems associated with aging. As the mechanism of action of these hormones has been elucidated, it has become clear that they are integral members of the immunological cytokine/chemokine network and share regulatory mechanisms with a wide variety of cytokines and chemokines. The members of this cytokine network induce and can be regulated by members of the suppressor of cytokine signaling (SOCS) family of intracellular proteins. In order to take advantage of the potential beneficial effects of hormones such as GH or PRL, it is essential to take into consideration the overall cytokine network and the regulatory effects of SOCS proteins.

show abstract

“…8 Later, a clinical investigation showed that hematologic patients with recombinant human growth hormone (rhGH) treatment underwent a faster recovery of platelets to 25 3 10 9 /L after intensive chemotherapy. 9 All the published data imply that GH may have a functional role in regulating thrombopoiesis. However, the direct effect of GH on thrombopoiesis remains unclear.…”

Section: Introductionmentioning

confidence: 99%

hGH promotes megakaryocyte differentiation and exerts a complementary effect with c-Mpl ligands on thrombopoiesis

Xu¹,

Wang²,

Shen³

et al. 2014

Blood

View full text Add to dashboard Cite

show abstract

Use of physiological doses of human growth hormone in haematological patients receiving intensive chemotherapy promotes haematopoietic recovery: a double-blind randomized, placebo-controlled study

Cited by 15 publications

References 24 publications

Enhancing T cell reconstitution after hematopoietic stem cell transplantation: A brief update of the latest trends

Enhancing T cell reconstitution after hematopoietic stem cell transplantation: A brief update of the latest trends

Neuroendocrine hormones such as growth hormone and prolactin are integral members of the immunological cytokine network

hGH promotes megakaryocyte differentiation and exerts a complementary effect with c-Mpl ligands on thrombopoiesis

Contact Info

Product

Resources

About